BREAKING NEWS

New Company Will Build Upon Strength of Current Therapies for Hemophilia A and B
New CDC data show large percentage of antibiotics misused in outpatient settings
NEI-funded study of bevacizumab and ranibizumab examines their effects at five years
Better prevention, care will help cut more infections, said researchers from Penn Medicine and Johns Hopkins
Allergan’s rosuvastatin calcium joins a $6.5 billion market
Subcutaneous nonopioid relieves pain with less toxicity and abuse potential
First and only FDA-approved drug for Parkinson-associated hallucinations and delusions
Registry will provide long-term safety and effectiveness data
Possible link to long wait times for VA care

P&T April 2016
Table of Contents

Features

Rules proposed by the Centers for Medicare and Medicaid Services would change discharge policies at hospitals and long-term care facilities and update conditions of participation with a focus on medication reconciliation and pharmacist responsibilities.
ASHP Foundation 2016–2020 Forecast
An American Society of Health-System Pharmacists Research and Education Foundation report predicts trends in health care delivery and financing, drug development and therapeutics, pharmaceutical marketplace, pharmacy workforce, and more.
Vaccine Spotlight
A new combination vaccine condenses the final administration of doses in the series of two recommended childhood vaccinations into a single injection.
Zika virus infection has emerged as the world’s newest health threat, linked to microcephaly in infants and Guillain–Barré syndrome in adults. We address the rapid global spread of this disease, and the prospects for successful prevention and treatment.
Meeting Highlights
Featured topics: benzhydrocodone, hydrocodone, and an opioid taper program at the American Academy of Pain Medicine; and disruption of the gut microbiome by drugs plus new approaches to depression at the Integrative Healthcare Symposium.
Pipeline Plus
Vasculitis, a group of heterogeneous disorders characterized by inflammation and necrosis of the blood vessels, has but one treatment approved by the Food and Drug Administration. However, six novel biologic candidates are in late-stage development.

Departments

Medication Errors
Improving medication safety during transitions in care.
Prescription: Washington
Tighter P&T committee rules proposed for NAIC model act.
Approvals, new indications, regulatory activities, and more
Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey) for combination HIV-1 therapy; dapsone gel, 7.5% (Aczone) for acne vulgaris; extended-release tofacitinib (Xeljanz XR) for rheumatoid arthritis; and brivaracetam (Briviact) for epilepsy
Drug Forecast
Paliperidone palmitate three-month injection (Invega Trinza): the first four-times-a-year, long-acting injectable antipsychotic agent for schizophrenia